CBLC 137

Drug Profile

CBLC 137

Alternative Names: CBL-0137; CBLC-137; Curaxin CBL0137

Latest Information Update: 03 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cleveland BioLabs
  • Developer Cleveland BioLabs; Incuron
  • Class Carbazoles; Small molecules
  • Mechanism of Action Apoptosis stimulants; DNA intercalators; NF-kappa B inhibitors; SSRP1 protein inhibitors; Tumour suppressor protein p53 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Haematological malignancies; Solid tumours

Most Recent Events

  • 09 Dec 2017 Pharmacodynamics data from preclinical studies in Acute myeloid leukaemia presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-2017)
  • 01 Jan 2017 Phase-I clinical trials in Haematological malignancies (Second-line therapy or greater) in USA (IV) (NCT02931110)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Second-line therapy or greater) in Russia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top